/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and its partner Medison.
/PRNewswire/ Hansa Biopharma AB, Hansa (Nasdaq: HNSA) (Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today welcomes.
The 7th IFPA Conference will be held June 27-29, 2024 in Stockholm Sweden. Dermatologists, rheumatologists, and experts from around the world will gather to share breakthroughs in psoriatic disease research.
/PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and.
netProviders har stärkt organisationen ytterligare genom rekrytering av expertkompetens di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.